A new journal where molecular biology meets clinical research

The European Molecular Biology Organization (EMBO) has announced the introduction of EMBO Molecular Medicine, a new journal dedicated to a research discipline focused on the interface between molecular biology and clinical research. The new journal, launching in 2009, will publish original research offering molecular insights into cellular and systemic processes underlying defined human diseases as well as potential clinical applications for diagnosis, prevention and therapy.

In line with EMBO's reputation for promoting the very best in the molecular life sciences, a renowned group of senior editors and an equally well respected advisory board assure published articles of the highest scientific quality following rapid, transparent and rigorous peer review.

"EMBO Molecular Medicine offers a unique opportunity to broadly distribute new findings in biomedical research and to strengthen links between clinicians and molecular biologists," said Hermann Bujard, EMBO Director. "We hope that published papers will lead to advances that will improve the detection, diagnosis and clinical management of diseases."

Articles will appear online and in print. In addition to research articles, the journal will publish review articles and editorials with innovative formats targeting a broad and unspecialised audience. A new format of review article, called Bridging the Gap, will aim to help molecular biologists and clinical researchers to understand each other's perspectives and to define common goals.

Submissions are invited from research groups at universities, independent research laboratories and pharmaceutical and biotechnology companies worldwide. EMBO Molecular Medicine offers free access to all content for the first two years of publication.

EMBO Molecular Medicine is published for EMBO by Wiley-Blackwell (the scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, Inc.) and joins the EMBO family of leading peer-reviewed journals - The EMBO Journal, EMBO reports and Molecular Systems Biology - that span a broad spectrum of topics of molecular biology and reflect how science is shaping the world.

For further information, please visit:
http://www.nature.com/emboj/index.html

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...